Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Fantin · SciRah

Researcher profile · Semantic Scholar

V. Fantin

Share profile

V. Fantin — researcher profile on SciRah

h-index: 40
Works: 109
Citations: 18K

Most-cited papers

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
L. Dang, D. W. White, S. Gross, Bryson D. Bennett +16 more
2010Nature4,046 citations
Semantic Scholar
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
M. Figueroa, Omar Abdel-Wahab, Chao Lu, P. Ward +22 more
2010Cancer Cell2,733 citations Open access
Semantic Scholar
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate
P. Ward, Jay Patel, David R. Wise, O. Abdel-Wahab +12 more
2010Cancer Cell1,982 citations Open access
Semantic Scholar
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.
V. Fantin, J. St-Pierre, P. Leder
2006Cancer Cell1,683 citations Open access
Semantic Scholar
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
G. Garcia-Manero, Hui Yang, Carlos E. Bueso-Ramos, A. Ferrajoli +17 more
2008Blood1,158 citations Open access
Semantic Scholar
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
S. Gross, R. Cairns, M. Minden, E. Driggers +9 more
2010Journal of Experimental Medicine746 citations Open access
Semantic Scholar
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1st and 2nd generation ALK inhibitors in pre-clinical models
H. Zou, L. Friboulet, D. Kodack, Lars D. Engstrom +29 more
2015Cancer Cell463 citations Open access
Semantic Scholar
Detection of 2-Hydroxyglutarate in IDH-mutated Glioma Patients by Spectral-editing and 2D Correlation Magnetic Resonance Spectroscopy
O. Andronesi, Grace S. Kim, E. Gerstner, T. Batchelor +4 more
2012Science Translational Medicine404 citations Open access
Semantic Scholar
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
R. Piazza, S. Valletta, N. Winkelmann, S. Redaelli +24 more
2012Nature Genetics396 citations Open access
Semantic Scholar
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
M. F. Amary, S. Damato, D. Halai, M. Eskandarpour +14 more
2011Nature Genetics396 citations
Semantic Scholar
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
E. Galanis, K. Jaeckle, M. Maurer, J. Reid +13 more
2009Journal of Clinical Oncology364 citations Open access
Semantic Scholar
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
W. Pope, R. Prins, M. A. Thomas, R. Nagarajan +17 more
2011Journal of Neuro-Oncology302 citations Open access
Semantic Scholar
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
K. Yen, M. Bittinger, Shinsan M. Su, V. Fantin
2010Oncogene291 citations Open access
Semantic Scholar
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
H. Zou, Qiuhua Li, Lars D. Engstrom, Melissa West +19 more
2015Proceedings of the National Academy of Sciences of the United States of America258 citations Open access
Semantic Scholar
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy
Christina H. Eng, Zun-Cai Wang, Diane Tkach, L. Toral‐Barza +16 more
2015Proceedings of the National Academy of Sciences of the United States of America232 citations Open access
Semantic Scholar
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
Janeta Popovici-Muller, J. Saunders, F. Salituro, J. Travins +15 more
2012ACS Medicinal Chemistry Letters200 citations Open access
Semantic Scholar
Missense mutations in the BCS1L gene as a cause of the Björnstad syndrome.
J. T. Hinson, V. Fantin, J. Schönberger, N. Breivik +15 more
2007New England Journal of Medicine197 citations Open access
Semantic Scholar
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
L. Dang, D. W. White, S. Gross, Bryson D. Bennett +16 more
2009Nature175 citations Open access
Semantic Scholar
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
V. Fantin, A. Loboda, C. Paweletz, R. Hendrickson +13 more
2008Cancer Research164 citations Open access
Semantic Scholar
Mitochondriotoxic compounds for cancer therapy
V. Fantin, P. Leder
2006Oncogene147 citations Open access
Semantic Scholar
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
V. Fantin, V. Richon
2007Clinical Cancer Research117 citations Open access
Semantic Scholar
Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
Casey L. Quinlan, S. Kaiser, Ben Bolanos, D. Nowlin +11 more
2017Nature Chemical Biology115 citations
Semantic Scholar
Vorinostat
V. Richon, V. Fantin, J. Ricker, S. Frankel
2017Reactions weekly108 citations
Semantic Scholar
Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
Naval P. Shanware, Kevin Bray, Christina H. Eng, Fang Wang +4 more
2014Nature Communications83 citations Open access
Semantic Scholar
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
B. Gomes, Grégory Driessens, D. Bartlett, Danying Cai +24 more
2018Molecular Cancer Therapeutics77 citations Open access
Semantic Scholar
Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2
Stephen G. Dann, M. Ryskin, A. Barsotti, Jonathon Golas +14 more
2015EMBO Journal63 citations Open access
Semantic Scholar
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Pei-Pei Kung, E. Rui, S. Bergqvist, Patrick Bingham +34 more
2016Journal of Medicinal Chemistry55 citations Open access
Semantic Scholar
Preclinical target validation using patient-derived cells
A. Edwards, C. Arrowsmith, C. Bountra, Mark E. Bunnage +57 more
2015Nature reviews. Drug discovery54 citations
Semantic Scholar
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
M. Kashyap, C. Amaya-Chanaga, Deepak Kumar, Brett H. Simmons +15 more
2017Journal of Hematology & Oncology51 citations Open access
Semantic Scholar
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.
Shu-Hui Liu, Yin Gu, Bernadette Pascual, Zhengming Yan +24 more
2017Blood Advances47 citations Open access
Semantic Scholar
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth
A. Barsotti, M. Ryskin, Wenyan Zhong, Wei-Guo Zhang +14 more
2015OncoTarget47 citations Open access
Semantic Scholar
Orally Bioavailable Small Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression Through Blockade of Adenosine Production.
Xiao-Hui Du, Jared T. Moore, Brian R Blank, J. Eksterowicz +18 more
2020Journal of Medicinal Chemistry42 citations Open access
Semantic Scholar
ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells
Mindy I. Davis, R. Pragani, Janeta Popovici-Muller, S. Gross +9 more
201341 citations
Semantic Scholar
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR
Peter J. Belmont, P. Jiang, T. McKee, Tao Xie +18 more
2014Science Signaling40 citations
Semantic Scholar
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
Yan-Yan Zhang, Erika Saavedra, R. Tang, Yin Gu +10 more
2017Scientific Reports39 citations Open access
Semantic Scholar
Survival of the fittest: metabolic adaptations in cancer.
M. Berardi, V. Fantin
2011Current Opinion in Genetics and Development32 citations
Semantic Scholar
Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).
Y. Rew, Xiao-Hui Du, J. Eksterowicz, Hai-Ying Zhou +16 more
2018Journal of Medicinal Chemistry26 citations Open access
Semantic Scholar
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels
D. Pollyea, H. Kohrt, Bing M. Zhang, J. Zehnder +8 more
2012Leukemia and Lymphoma23 citations Open access
Semantic Scholar
Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.
H. Zou, Lars R. Engstrom, Qiuhua Li, M. Lu +12 more
201318 citations
Semantic Scholar
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer
F. Chiaradonna, I. Barozzi, Claudia Miccolo, Gabriele Bucci +16 more
2015Antioxidants and Redox Signaling16 citations Open access
Semantic Scholar
Design and Synthesis of Pyridone-Containing 3 , 4-Dihydroisoquinoline-1 ( 2 H ) ‐ ones as a Novel Class of Enhancer of Zeste Homolog 2 ( EZH 2 ) Inhibitors
Pei-Pei Kung, E. Rui, S. Bergqvist, Patrick Bingham +34 more
201612 citations
Semantic Scholar
Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
W. Shakespeare, V. Fantin, Frank Y. Wang, A. Kohlmann +26 more
200912 citations
Semantic Scholar
Self-eating limits EGFR-dependent tumor growth.
V. Fantin, R. Abraham
2013Cell11 citations Open access
Semantic Scholar
Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.
H. Zou, Lars R. Engstrom, Qiuhua Li, M. Lu +18 more
20139 citations
Semantic Scholar
Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).
Xiao-Hui Du, J. Eksterowicz, Hai-Ying Zhou, Y. Rew +13 more
2019Journal of Medicinal Chemistry8 citations Open access
Semantic Scholar
Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
B. Warth, Amelia Palermo, Nicholas J. W. Rattray, N. Lee +10 more
2018bioRxiv8 citations Open access
Semantic Scholar
Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice
Yan-Yan Zhang, Erika Saavedra, R. Tang, Shu-Hui Liu +7 more
20158 citations Open access
Semantic Scholar
Abstract 4172: Activation of AR signaling by mifepristone enhances prostate cancer growth and impairs enzalutamide response
Hai-Ying Zhou, Nadine Jachan, Mallika Singh, Christopher Tran +14 more
20175 citations
Semantic Scholar
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.
Pei-Pei Kung, E. Rui, S. Bergqvist, Patrick Bingham +34 more
2016Journal of Medicinal Chemistry5 citations Open access
Semantic Scholar
2-Hydroxyglutarate in IDH mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels
D. Pollyea, H. Kohrt, Bing M. Zhang, J. Zehnder +8 more
20115 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Smeal×8
Invite
T. Smeal — researcher profile on SciRah
Shinsan M. Su×7
Invite
Shinsan M. Su — researcher profile on SciRah
Wen-Yue Hu×7
Invite
Wen-Yue Hu — researcher profile on SciRah
V. Richon×6
Invite
V. Richon — researcher profile on SciRah

×6

Invite

S. Yamazaki — researcher profile on SciRah

Invite

H. Gukasyan — researcher profile on SciRah

Invite

L. Dang — researcher profile on SciRah

Invite

S. Gross — researcher profile on SciRah

M. Bittinger×5

Invite

M. Bittinger — researcher profile on SciRah

Invite

H. G. Jang — researcher profile on SciRah

Invite

K. Yen — researcher profile on SciRah

Invite

D. Dinh — researcher profile on SciRah